Case 3:23-cv-14221-ZNQ-JBD Document 72 Filed 03/18/24 Page 1 of 2 PageID: 1838



U.S. Department of Justice Civil Division Federal Programs Branch 1100 L Street NW Washington, DC 20005

March 18, 2024

VIA ECF

Hon. Zahid N. Quraishi United States District Judge Clarkson S. Fisher Building & U.S. Courthouse 402 East State Street Trenton, NJ 08608

Re:

Novo Nordisk Inc. v. Becerra, No. 3:23-cv-20814-ZNQ-JBD Novartis Pharmaceuticals Corp. v. Becerra, No. 3:23-cv-14221-ZNQ-JBD

Dear Judge Quraishi:

Defendants' reply briefs in support of their motions for summary judgment in the abovecaptioned cases are currently due on March 22, *Novo Nordisk* ECF No. 24, and March 27, *Novartis* ECF No. 20. Defendants respectfully submit that their arguments have been sufficiently developed in prior filings and at oral argument (in these cases, as well as in *Bristol Myers Squibb* and *Janssen*). Accordingly, Defendants waive their right to file summary-judgment reply briefs in *Novo Nordisk* and *Novartis*, and will stand on their prior submissions.

Dated: March 18, 2024

Respectfully submitted,

BRIAN M. BOYNTON Principal Deputy Assistant Attorney General

BRIAN D. NETTER Deputy Assistant Attorney General

PHILIP R. SELLINGER United States Attorney

MICHELLE R. BENNETT Assistant Branch Director

<u>/s/ Stephen M. Pezzi</u> STEPHEN M. PEZZI Senior Trial Counsel CHRISTINE L. COOGLE MICHAEL J. GAFFNEY CASSANDRA M. SNYDER ALEXANDER V. SVERDLOV Trial Attorneys United States Department of Justice Civil Division, Federal Programs Branch 1100 L Street, NW Washington, DC 20005 Tel: (202) 305-8576 Email: stephen.pezzi@usdoj.gov

Counsel for Defendants